J. B. Chemicals & Pharmaceuticals Limited

Equities

JBCHEPHARM

INE572A01036

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:52 2024-03-28 am EDT 5-day change 1st Jan Change
1,649 INR +0.21% Intraday chart for J. B. Chemicals & Pharmaceuticals Limited +3.93% +1.54%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
J. B. Chemicals & Pharmaceuticals Limited Announces Demise of Ranjit Shahani, Chairman and Non-Executive, Independent Director CI
KKR Reportedly Considers Selling Controlling Stake in JB Pharma CI
Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,000 From INR1,970, Keeps at Buy MT
JB Chemicals' Consolidated Profit Climbs in Fiscal Q3; Shares Jump 4% MT
J.B. Pharma Seeks Acquisitions CI
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 07, 2024
J. B. Chemicals & Pharmaceuticals Appoints CFO MT
JB Chemicals Names CFO MT
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand RE
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
J. B. Chemicals & Pharmaceuticals Limited Appoints Narayan Saraf as the Chief Financial Officer, with Effect from February 23, 2024 CI
J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend for Financial Year 2023-24 CI
Transcript : J. B. Chemicals & Pharmaceuticals Limited - Shareholder/Analyst Call
J. B. Chemicals & Pharmaceuticals Limited Announces Execution of Trade Mark License Agreement with Novartis Innovative Therapies Ag and Promotion & Distribution Agreement with Novartis Healthcare Private Limited CI
JB Pharma Seeks Acquisitions CI
Jefferies Adjusts J.B. Chemicals & Pharmaceuticals' Price Target to INR1,680 From INR1,555, Keeps at Buy MT
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q2 2024 Earnings Call, Nov 08, 2023
J.B. Chemicals Records Rise in Fiscal Q2 Consolidated Net Profit MT
J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as an Additional Director CI
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
J.B. Chemicals' CFO Resigns MT
J. B. Chemicals & Pharmaceuticals Limited Announces Cessation of Lakshay Kataria, Chief Financial Officer and Key Managerial Personnel, Effective November 30, 2023 CI
J. B. Chemicals & Pharmaceuticals Limited Approves Final Dividend for the Year Ended March 31, 2023 CI
J B Chemicals Gets US FDA Nod for Doxepin Hydrochloride Capsules MT
J.B. Chemicals & Pharmaceuticals Limited Announces Abbreviated New Drug Application Approval by US FDA CI
Chart J. B. Chemicals & Pharmaceuticals Limited
More charts
J. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its therapeutic categories include gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives and pharmacovigilance. The Company's lozenges products include center-filled, soft-centered lozenges; center-filled, powder lozenges; herbal lozenges, and medicated lozenges. The Company offers a complete range of contrast media products including X-ray, MRI, and ultrasound in India as well as internationally. The Company produces a wide range of dosage forms, such as tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges and sips. Its brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA and Sporlac G, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1,649 INR
Average target price
1,887 INR
Spread / Average Target
+14.38%
Consensus